Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects

Completed · Phase 1

Conditions studied: Healthy

In brief

* Objective: * A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects. * Study Design: * Randomized,single-dose,2-way crossover.

Key facts

Study ID

NCT00944177

Run by

Torrent Pharmaceuticals Limited

Last updated by the study team

2009-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is at least 18 years old.
• Subject had no clinically significant abnormal lab values at the screening evaluation.
• Subject's drugs of abuse, Hepatitis B, Hepatitis C, and HIV screenings were negative or non-relative.
• Acceptable screening of ECG.
• Female subject's pregnancy test at screening is negative.
• Subject had no evidence of underlying disease at the pre-entry physical examination.
• Subject has given written consent to participate.
• Female subject has not received any injectable or implantable contraceptive for a period of six months preceding this study.
• Agreed to undergo at least a 14-day pre-dose washout.
• Beginning two weeks prior to dosing and throughout the study, female subject of childbearing potential agrees to utilize one of the following methods of contraception:
• Condom and topical spermicide
• Condom and diaphragm
• Intra-uterine device (I.U.D)
• Complete abstinence.
• Agree to abstain from consuming caffeine or alcohol for at least 48 hours. prior to study and throughout the blood collection periods.

You may not qualify if…

• History of treatment for alcoholism, substance abuse, or drug abuse with in the past 24 months.
• History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
• History of GRD, malabsorption syndrome, colon cancer, or chronic colitis, including Crohn's disease.
• History of treatment for asthma, hypoxemia, dehydration, sepsis, metabolic acidosis and congestive heart failure.
• Subject is pregnant or lactating.
• History of drug hyper sensitivity.
• Subject was treated with any investigational drug during the four weeks prior to initial dosing for the study.
• Subject smokes more then 15 cigarettes per day or uses tobacco products or currently uses nicotine products.

Where it is running

• Gateway Medical Research, Inc. — Saint Charles, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.